Innolake Biopharm
Latest round
- Series A
Last raised
- Jun 2023
Total raised
- $14M
Investors
- 3
About Innolake Biopharm
, trading as Innolake Biopharm, is a medical company that focuses on the research and development of therapeutics in the areas of oncology and autoimmune, which was recognized as a Chinese Next Unicorn enterprise and listed in 2021 China Biopharmaceutical Industry Innovation Top100 List. It has a branch and business operation office in Shanghai. Dr. Mingde Xia, the Chairman, CEO, and co-founder, served as director of the Johnson & Johnson Group and worked at China Pharmaceutical University and Yale University. He is also a director of the US-China Pharmaceutical Association (SAPA). The company engages in research and developing drugs for tumors and immune system diseases. It has established a production pipeline that includes small molecules, therapeutic antibodies, and ADC.
Who invested in Innolake Biopharm
3 investors across 1 round
See all investors in Innolake Biopharm
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jun 5, 2023
Amount
$14M
Investors
Questions about Innolake Biopharm
Who invested in Innolake Biopharm?
Innolake Biopharm has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Innolake Biopharm raised?
Innolake Biopharm has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Innolake Biopharm last raise money?
Innolake Biopharm's most recent round on record is a Series A, in Jun 2023.
What does Innolake Biopharm do?
, trading as Innolake Biopharm, is a medical company that focuses on the research and development of therapeutics in the areas of oncology and autoimmune, which was recognized as a Chinese Next Unicorn enterprise and listed in 2021 China Biopharmaceutical Industry Innovation Top100 List.
Where is Innolake Biopharm headquartered?
Innolake Biopharm is headquartered in Hangzhou, China.
Which VCs invest in companies like Innolake Biopharm?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Innolake Biopharm's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Innolake Biopharm? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.